

STUDY PROTOCOL

Open Access



Effectiveness of pulmonary rehabilitation for patients with asthma: study protocol of a randomized controlled trial (EPRA)

Konrad Schultz^{1*}, Hildegard Seidl², Danijel Jelusic¹, Rupert Wagner¹, Michael Wittmann¹, Hermann Faller³, Dennis Nowak⁴ and Michael Schuler³

Abstract

Background: Asthma patients are enrolled in multimodal pulmonary rehabilitation (PR) programs. However, available data for the effectiveness of PR in asthma are sparse. Therefore, the primary aim of this randomized control trial (RCT) is to evaluate short-term (end of rehabilitation) and intermediate-term effectiveness (3 months after rehabilitation) of PR for patients with asthma regarding asthma control (primary outcome) and other outcomes. Secondly, moderator effects of gender, age, baseline asthma control, quality of life, and anxiety will be examined. Thirdly, a longitudinal follow-up study will explore the course of the outcomes over one year and the annual costs.

Methods: The EPRA study is a single-center randomized controlled waiting-list trial in the Bad Reichenhall Clinic. Inclusion criteria include a referral diagnosis for uncontrolled asthma, no cognitive impairment and no very severe co-morbidities that indicate significantly greater illness morbidity than asthma alone. In the intervention group (IG), participants will start PR within 4 weeks after randomization; participants of the control group (CG) will start PR 20 weeks after randomization. Data will be assessed at randomization (T0), after 4 weeks (T1; IG: begin of PR), 7 weeks (T2; IG: end of PR), and 20 weeks (T3, CG: begin of PR). The primary outcome is asthma control at T2/T3. Secondary outcomes are health-related quality of life, functional exercise capacity, dyspnea, anxiety, depression, subjective self-management skills, illness perceptions, sick leave and subjective work ability. Outcomes will be analyzed with analysis of covariance, including baseline values of the respective outcomes as covariates. Healthcare costs will be analyzed with a gamma model with a log-link.

A longitudinal follow-up study will generate additional data at 3/6/9/12 months after PR for both IG and CG. Latent change models will be used to analyze the course of the primary and secondary outcomes. Annual cost differences before and after rehabilitation will be compared by paired t-test.

Discussion: This RCT will determine the effectiveness of a complex inpatient PR for asthma patients concerning asthma control. Furthermore, important medical and economic information regarding the effectiveness of PR as part of the long-term management of patients with uncontrolled asthma will be generated.

Trial registration: German Clinical Trials Register (DRKS00007740, May 15, 2015). Protocol version: 1.0 (December, 23, 2016).

Keywords: Pulmonary rehabilitation, Asthma, RCT, Longitudinal study, Asthma control, ACT, Inpatient rehabilitation, Randomized controlled trial, Longitudinal, Economic evaluation

* Correspondence: konrad.schultz@klinik-bad-reichenhall.de

¹Klinik Bad Reichenhall, Center for Rehabilitation, Pulmonology and Orthopedics, Bad Reichenhall, Germany

Full list of author information is available at the end of the article



Background

Introduction

Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals [1]. Asthma was defined by the Global Initiative for Asthma (GINA) as a heterogeneous disease, usually characterized by chronic airway inflammation and a history of respiratory symptoms that vary over time and in intensity, including wheeze, shortness of breath, chest tightness and cough, together with variable expiratory airflow limitation [1]. Thus, the diagnosis of asthma is primarily based on clinical symptoms [2]. In spite of the availability of effective medications, it remains incurable. Various cross-sectional studies have shown a high number of patients with poorly controlled asthma in many countries [3, 4]. Therefore, new approaches to improve asthma control (AC) are urgently required.

Pulmonary rehabilitation (PR) is widely accepted as an effective treatment for patients with chronic respiratory diseases, especially for chronic obstructive pulmonary disease (COPD) [5]. In Europe and North America, asthma patients are also commonly enrolled in PR programs [6], but the available data regarding the effectiveness of PR for asthma patients are sparse. Only very few randomized studies [7, 8] concerning the effectiveness of a multimodal PR program in asthma have been published. All had certain methodological limitations, so that they weren't considered for international evidence-based asthma guidelines [1, 2].

However, the effectiveness of the essential individual components of PR, such as patient education [9, 10], respiratory physiotherapy [11, 12] and aerobic exercise training [13–18] has been shown in several randomized controlled trials (RCTs). As a complete PR program is expected to be at least as effective as these single components, the German National Disease Management Guideline [19] recommends PR for asthma patients if physical, mental or social consequences of the illness are constraining and persist during daily life despite adequate medical therapy.

Besides the two RCTs [7, 8], a limited number of observational studies have been published in the international [20–24] and German literature [25–27]. They have shown positive effects regarding quality of life, clinical symptoms, physical function, exacerbations, and health care resource utilisation. However, up to now, no RCTs have addressed the question whether and how long asthma control improves after PR. Therefore, such a study was strongly recommended by the German National Disease Management Guideline [19].

This lack of evidence is of particular relevance since asthma is a common indication for PR in Europe and in the US [6], and is the most frequent indication for PR in Germany [28]. Therefore, the main objective of the

EPRA-RCT is to fill the knowledge gap for PR in asthma. Moreover, there is little empirical data regarding the long-term course of AC, quality of life and self-management skills after PR for asthma and the cost-effectiveness. As part of the EPRA study a follow-up assessments at 6, 9 and 12 months after PR will be provided.

Study aims

The primary aim of this RCT is to evaluate the effectiveness of PR for patients with asthma on short (end of rehabilitation) and intermediate-term (3 months after rehabilitation) outcomes as compared to a waiting-list control group. We hypothesize that pulmonary inpatient rehabilitation is superior regarding mean change in AC at 3 months after rehabilitation (primary outcome). Furthermore, we expect superior effectiveness of the pulmonary rehabilitation regarding health related quality of life (HRQoL), functional exercise capacity, dyspnea, anxiety, depression, subjective self-management skills, illness perceptions, sick leave, as well as subjective work ability (secondary outcomes). In addition, moderator effects of (a) gender, (b) age, (c) baseline AC, (d) baseline HRQoL and (e) baseline anxiety will be examined. Moreover, in a longitudinal follow-up study, the course of primary and secondary outcomes over one year and the annual costs before and after rehabilitation will be explored.

Methods

Study design and data collection

We use a two part-study design, combining a randomized controlled trial (RCT) and a longitudinal follow-up design.

The main study is a randomized control superiority trial, comparing the intervention group (IG) with a waiting-list control group (CG). For legal reasons, any insurant of the statutory German Pension Insurance (GPI) whose application for medical rehabilitation was approved by the GPI will receive a rehabilitative intervention. Therefore, it is not possible to use an entirely untreated CG, but a waiting-list CG can be realized. After inpatient rehabilitation in the Bad Reichenhall Clinic has been approved by the GPI, patients receive a letter informing about the study and screening for their eligibility. If no response is received within 14 days, a reminder will be sent to the patients. If patients meet the inclusion criteria, they are asked to participate. After consent has been obtained, participants will be randomized to the IG or CG. In the IG, participants will start inpatient rehabilitation within 4 weeks after randomization. Data will be assessed at randomization (T0), at the beginning (T1), the end (T2), and three months after inpatient rehabilitation (T3). The CG will start inpatient rehabilitation five

months (i.e. 20 weeks) after randomization. CG data will be assessed at randomization (T0), at four weeks (T1), at seven weeks (T2) and at 20 weeks (T3, beginning of inpatient rehabilitation) after randomization. The crucial reference intervals for the primary research questions are T0 to T2 and T0 to T3 for both IG and the CG. Since CG starts PR 19 to 20 weeks after T0, which is 3 months after the discharge time-point of IG, it will be possible to compare the results of IG with those of the (still) untreated CG during these initial 19 to 20 weeks. However, it may be possible that for the CG, arrival at the rehabilitation clinic (at T3) already has an effect on several outcome parameters. To estimate this “arrival effect”, an additional measurement time point (T3a) for the CG at 10 (+/-3) days before T3 has been included.

The second part of the study is a longitudinal cohort study. In addition to the data collected in the first part of the study (RCT), data at 6, 9 and 12 months after inpatient rehabilitation in the IG and data at the end of and at 3, 6, 9 and 12 months after inpatient rehabilitation in the CG will be collected. Longitudinal data from both groups will be combined to one sample. Fig. 1 illustrates the study design. Note that measurement time points of the IG and CG have a parallel timing only from T0 to T3. Participants not returning the postal questionnaires on time will be reminded by phone. If necessary, questionnaires will be sent again by mail to the patient.

Patient selection

Patients are eligible for the study if they are approved for PR, have a physician diagnosis of asthma (ICD-10: J45) at T0 and have uncontrolled asthma based on an


Asthma Control Test (ACT) <20 [1, 29, 30]. Patients will be excluded if they have cognitive impairment, inadequate German language ability, or severe concomitant diseases that might mask the results of asthma rehabilitation (for example cancer and severe cardiac/orthopedic or psychiatric comorbidities). The initial diagnosis of asthma will be confirmed by a pulmonologist at admission to inpatient rehabilitation. If the initial diagnosis cannot be confirmed, the patient will be excluded from the study.

Randomization

Participants will be recruited consecutively. All patients meeting the inclusion criteria and providing informed consent are randomly assigned to the IG or CG by a study nurse at the time of their PR approval. Randomization will be stratified according to age. The randomization list (with computer-generated random numbers) is created by the Department of Medical Psychology and Psychotherapy, Medical Sociology and Rehabilitation Sciences at the University of Würzburg (concealed allocation).

Blinding

Patients themselves cannot be blinded due to the time-point of the start of their inpatient rehabilitation. However, those who deliver the rehabilitation treatment are unaware whether the patient is a study participant, a participant of the IG or the CG, or a regular inpatient outside the study.



Sample size

Calculation of sample size is based on our primary outcome, the ACT, assessed three months after the inpatient rehabilitation. A previous longitudinal study of asthma patients in the Bad Reichenhall Clinic (without a CG) showed changes between start of inpatient rehabilitation and three months after inpatient rehabilitation of (Cohen's) $d > 0.5$ [25]. However, this value might overestimate the effect of inpatient rehabilitation compared to a control group. Therefore, sample size was calculated to detect a difference of $d = 0.3$ at T3 between the IG and CG. Using $\alpha = 0.05$ and power = 0.8, 352 participants are required, but assuming a drop-out rate of 30%, a total of $n = 504$ patients will be recruited [26].

Latent curve models will be used to analyze the course of the primary outcome in the longitudinal follow-up study. As a rule of thumb, $N > 100$ cases should be included in the computation of these models. Even with a conservatively estimated drop-out rate of 50% until T6 for IG and T8 for CG, $N = 152$ patients would remain in the study, which is sufficient.

Intervention

As shown in Fig. 1, both groups receive a 3-week PR that meets the structural requirements of German healthcare insurance providers [31, 32]. The PR is carried out by a multi-professional team (physicians, psychologists, physiotherapists, sports scientists, social workers, nutritional consultants) and will be tailored individually to each patient's needs. The rehabilitation program will be reviewed at least once a week as part of the doctor's weekly rehabilitation ward round.

The rehabilitation program includes the following non-drug therapy components (O = obligatory for all participants, except those with individual contraindications, F = facultative if needed):

1. Physical training (O) consisting of three obligatory components: a) endurance training scheduled for 5 units per week for 45–60 min each, during which outdoor sports and training in water (e.g. Aqua Fitness, Nordic Walking) are performed. Exercise intensity is controlled by BORG Scale and heart rate; b) strength training scheduled for 3 sessions per week of 45–60 min each and c) whole-body vibration-training scheduled 7 times per week. In addition, inspiratory muscle training (F) is provided for patients with inspiratory muscle weakness and is scheduled for 7 sessions per week, each for 21 min, of which 2 per week are supervised.
2. Comprehensive patient education (O) consisting of two obligatory components: a.) patient education regarding asthma for one week with 7 units of 45 min; b.) one session of practical medical inhalation

training and/or peak flow meter use for 60 min. In addition, patients also receive allergy awareness and trigger avoidance training (F) if required (one 60-min session).

3. Respiratory physiotherapy (O) consisting of 3 units of group respiratory physiotherapy per week with learning of pursed lips breathing (O) for 45 min each. If necessary, patients may also receive the following optional components (F) including: a) individual breathing training by physiotherapists; b) training of Buteyko breathing techniques [29] for patients with dysfunctional breathing [30]; c) physiotherapy seminar on coughing techniques for patients with cough problems; d) mucolytic inhalation therapies (e.g. saline inhalation, for patients with mucostasis (4).
4. Psychosocial support (F) such as social counseling, individual psychological counseling and/or group therapy will be offered if necessary (Patient Health Questionnaire (PHQ-9) > 9 points, Generalized Anxiety Questionnaire (GAD-7) > 9 points or if indicated by their physicians).
5. Comprehensive smoking cessation program (F) will be offered to all smokers.
6. Comprehensive nutritional counseling (F) will be offered to patients with food intolerance or allergies or over- and underweight.

In addition, patients will receive a routine check-up and if necessary, current asthma medications will be optimized according to the current guidelines. This is an obligatory part of the rehabilitation in Germany. Any changes to medications will be documented. Adverse events and complications during rehabilitation are recorded by the physicians on a standardized basis in the medical survey sheet at the end of rehabilitation.

Outcomes and measures

The primary outcome is the mean change in AC, assessed by ACT. Secondary outcomes include mean changes in HRQoL, 6-min walk distance (6-MWD) and Sit-to-stand-test, lung function parameters, Eosinophils, dyspnea, depression, anxiety, smoking habits, illness representations, self-management skills, work ability, subjective prognosis of return to work, sick leave, medication beliefs and medication adherence. Measurement instruments for all outcomes and measurement occasions can be found in Table 1. Lung function parameters, 6-MWD, FeNO, and Eosinophils are assessed at the start and the end of the inpatient rehabilitation by staff of the PR. All other outcomes are assessed via questionnaires.

Table 1 outcome measures

| Outcome | measured by/Instrument | T0 | T1 | T2 | T3A (CG) | T3 | T4 | T5 | T6 | T7 (CG) | T8 (CG) |
|----------------------------|---|----|----|----|----------|----|----|----|----|---------|---------|
| Asthma control | Asthma control test (ACT) [29, 30] | X | X | X | X | X | X | X | X | X | X |
| Lung function, blood gases | FEV1, FEV1/VC, SRtot, VC, RV, PaO2, PaCO2, [50, 51] | | IG | IG | | CG | CG | | | | |
| Exercise capacity | 6MWT [53] | | | | | | | | | | |
| Allergy | Total Ig E, specific Ig E-Screening (ImmunoCAP®) | | IG | IG | | CG | CG | | | | |
| Asthmatic inflammation | Fractional exhaled nitric oxide (FeNO) [56], Eosinophils | | IG | IG | | CG | CG | | | | |
| QoL | Saint George's Respiratory Questionnaire (SGRQ) [35] | X | X | X | X | X | X | X | X | X | X |
| QoL | Asthma Quality of Life Questionnaire (AQLQ) [36] | X | X | X | X | X | X | X | X | X | X |
| QoL | EQ-5D-5L [37, 38, 57] | X | X | X | X | X | X | X | X | X | X |
| QoL | Global Rating of Change Scale (GROC-scale) [39] | | | X | X | X | X | X | X | X | X |
| Symptoms | Numerical rating scale for dyspnoea, cough, sputum, pain [40] | X | X | X | X | | X | X | X | X | X |
| Dysfunctional breathing | Nijmegen Questionnaire (NQ) [58] | X | X | X | X | | | | | X | X |
| Depression | Patient Health Questionnaire (PHQ) [59] | X | X | X | X | | X | X | X | X | X |
| Anxiety | Generalized Anxiety Disorder Questionnaire (GAD 7) [60] | X | X | X | X | | X | X | X | X | X |
| Fatigue | Brief Fatigue Inventory (BFI) [41] | X | X | X | X | | | | | | |
| Illness Perception | Illness Perception Questionnaire (IPQ-R) German Version [45] | X | X | X | X | | X | X | X | X | X |
| Resource Use | FIM-Lu, modification of FIMA [52] | X | | | X | | X | X | X | X | X |
| Work ability | Work Ability Index (WAI) Items 1 and 4 [61] | X | X | X | X | | X | X | X | X | X |
| SPoRTW | SPE-Scale [55] | X | X | X | X | | X | X | X | X | X |
| Self-management | Health Education Impact Questionnaire (heiQ), Scale "Skill and technique acquisition" | X | X | X | X | | X | X | X | X | X |
| Smoking habits | Questionnaire (developed) | X | | | X | | X | X | X | X | X |
| Sport behaviour | Questionnaire (developed) | X | | | X | | X | X | X | X | X |
| Medication beliefs | Brief Medication Questionnaire (BMQ) [62] | X | X | X | X | | | | X | X | X |
| Adherence | Medication Adherence Report Scale (MARS) [63] | X | X | X | X | | | | X | X | X |
| Sick leave | Questionnaire (developed) | | | | IG | | X | X | X | X | X |

Notes: QoL: Quality of Life; SPoRT: Subjective prognosis of return to work; IG: assessment only in intervention group; CG: assessment only in control group

Assessment of outcomes

Asthma control

Asthma Control will be assessed by using the Asthma Control Test (ACT) [30, 33]. The ACT consists of five items that assess (1) activity limitation, (2) daytime shortness of breath, (3) awaking due to asthma symptoms, (4) needed puffs of reliever medication and (5) a global judgment of asthma control. All items refer to the last 4 weeks. They are scaled from 1 to 5. The sum of scores indicates asthma control. An ACT score of 20 – 25 indicates controlled asthma and of <20 indicates uncontrolled asthma. A minimal important difference about 3 was identified [34].

Health related quality of life

Asthma specific HRQoL will be assessed by both, the Saint George's Respiratory Questionnaire (SGRQ) [35] and the standardized version of the Asthma Quality of

Life Questionnaire (AQLQ) [36]. The SGRQ uses 50 items to capture the three domains *Symptoms*, *Activity* and *Impacts* as well as a *Total* scale. All scales are computed by weighted sums of the respective items. The scores range from 0 (no impairment) to 100 (maximum impairment). A minimal important difference (MID) of 4 is established for COPD, a MID for asthma has not been reported up to now. The standardized version Asthma Quality of Life Questionnaire (AQLQ) contains 32 questions to capture the four domains *Symptoms*, *Activity limitation*, *Emotional function* and *Environmental stimuli* to measure the functional problems that are most troublesome to adults with asthma. The survey period covers the past 2 weeks. Each question is answered on a 7-point scale (1 = severely impaired - 7 = not impaired at all). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items from those domains.

Generic HRQoL of patients is measured using the Euroqol questionnaire (EQ-5D-5L) and the EQ visual analogue scale (VAS). The EQ-5D-5L [37] is a standardized instrument applicable to a wide range of health conditions for use as a measure of health outcome. It is especially suited to cost effectiveness analyses as it can be used to generate quality-adjusted life years [38]. The descriptive system of the EQ-5D-5L comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has five levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. A German utility index is currently being developed.

Subjective health

Global rating of change (GRC) [39] in subjective health is assessed using a single item that compares current subjective health with subjective health at the beginning of the inpatient rehabilitation. The response scale ranges from -7 (much worse) over 0 (no change) to 7 (much better).

Symptoms

Severity of dyspnea, cough, sputum and pain will be assessed with response to seven 11-point numeric rating scales [40]. Scale values range from 0 (no symptoms) to 10 (worst imaginable symptom severity).

Fatigue

The Brief Fatigue Inventory (BFI) will be used to measure fatigue. This short questionnaire assesses severity of and impairment from fatigue with ten questions. The subscales and the total score range from 0 to 10, with higher values indicating higher severity/impairment. A German version exists and has been proven reliable and valid [41].

Depression and anxiety

The PHQ-9 and the GAD-7 will be used to assess depression [42] and anxiety [43, 44]. All items are scored on a 4-point Likert scale (0 = not at all, 1 = several days; 2 = more than half of the days; 3 = nearly all days). Besides using the sum of scores (which range from 0 to 27 in PHQ and 0 to 21 in GAD-7), we will also classify individuals with values of >10 as indicating a clinically relevant depressive disorder (PHQ-9) or a clinically relevant anxiety disorder (GAD-7).

Illness representation

The 9-item Brief-Illness Perception Questionnaire (B-IPQ) [45] will be used to capture 8 aspects of *illness representations* (i.e how illness perceived by the patient: *Consequences, Timeline, Personal control, Treatment control, Identity, Concern, Understanding* and *Emotional*

response). Each aspect is assessed by one item, except for *Emotional response*, which is assessed by two items. All items use a 0 to 10 response scale. Furthermore, perceived causes of asthma attacks are assessed via an open-ended response item, which asks for the three most important causal factors of their illness.

Subjective self-management

Subjective self-management will be assessed using the *Skill and technique acquisition* scale from the Health Education Impact Questionnaire (heiQTM, [46, 47]). The items are scored on a 4-point response scale (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree). The overall score is computed as the unweighted mean of all items, with higher values indicating a higher subjective judgement of self-management.

Medication adherence and medication beliefs

Patients will complete the Medication Adherence Report Scale (MARS-D) [48]. This is a 5-item questionnaire with a 5-point response scale (1 = always to 5 = never). The sum of the individual answers can range from 5 to 25 points, with higher values indicating better medication adherence. The 10-item Brief Medication Questionnaire (BMQ) [49] will be used to assess patient's medications beliefs on two scales. The scale *Necessity* assesses patients' beliefs about the necessity of prescribed instruments and the scale *Concern* assesses patients' concerns about prescribed medications. Both scales range from 5 to 25 points with higher values indicating higher belief of necessity/higher concerns.

Lung function measurement

Forced expiration in one second (FEV₁), vital capacity (VC), residual volume (RV) and total specific resistance (SR_{tot}) are determined using spirometry and body plethysmography (MasterLab, CareFusion, Hoechst, Germany) before and after bronchodilation with a short-acting bronchodilator in accordance with recommendations of the national guidelines [50, 51].

Resource use

Resource use will be determined based on answers to the FIMA-Lu questionnaire, a modified Version of the FIMA questionnaire, a German instrument to assess health-related resource use [52]. For direct costs, the number of visits to a general practitioner, specialist care, ambulatory clinics in hospital, physiotherapy, days spent in hospitals and intensive care units and medication administered will be documented. For indirect costs, work absenteeism days will be documented.

Exercise Capacity

The 6-MWD will be measured using a track length of 30 m according to the European Respiratory Society/American Thoracic Society technical standards [53]. At T0 and T1 respectively, each patient performs the test twice with an interval of one hour. The best test will be included for analysis.

Work ability

Subjective work ability will be assessed by the first item of the Work Ability Index (WAI), the *Work Ability Score* (WAS). It compares current subjective work ability to the lifetime's best. The 11-point scale ranges from 0 (complete incapacity to work) to 10 (lifetime's best work ability). The WAS shows high correlations with the overall WAI score [54]. Furthermore, the 4th Item of the WAI is used to assess health-related limitation of current work ability, with values ranging from 1 (total incapacity to work) to 6 (no limitation). In addition, subjective prognosis of employment status will be assessed using the 3- items of the Subjective Prognostic Employment Scale (SPE Scale). The three items assess patient's belief (a) to remain at work until retirement and (b) whether their health will be permanently jeopardized and (c) whether they are considering applying for a disability pension [55].

Sport activity, smoking habits and medication use

Two items will be used to assess sport activity. In Item 1, the patient indicates whether he or she exercises regularly (at least 2 times per week) and in item two the kind of exercise performed (e.g. gym, sports club, lung sport group). Current smoking status (current smoking yes or no) and number of cigarettes per day will be documented. Furthermore, patients' use of antibiotics or cortisone in the last three months (yes/no; number of uses) will be documented.

Socio-demographic data and employment

Information regarding socio-demographic data and employment status will be collected.

Data management Data of all measurement time-points will be collected in the Bad Reichenhall Clinic. Questionnaire data will be entered into Microsoft Excel by two study nurses (independent double data entry by two individuals). A unique ID number will be assigned to each patient and personal data (name, address) will be stored in a completely separate file. The list with assigned ID numbers and personal data will be stored in the Bad Reichenhall Clinic and will not leave the center. Other anonymized data will be sent to the University of Wuerzburg and the Helmholtz Zentrum Munich for further data management and data analyses.

Statistical methods

Primary and secondary outcomes will be analyzed according to the intention to treat approach [56]. All randomized patients will be included in the analysis. Missing data fulfilling the assumption of missing (completely) at random will be imputed using multiple imputation procedures [57]. In addition, because it may be possible that some patients will not start with the inpatient rehabilitation or decide to drop-out of the study, we will also analyze results based on a "per protocol" approach [58, 59] including only patients remaining in the study until T3.

The analysis of the primary and secondary outcomes at T2/T3 will use analysis of covariance (ANCOVA) with treatment group as a fixed effect and baseline value of the respective outcome as a covariable. Adjusted mean differences and confidence intervals will be reported. In addition, moderating effects [60] of the following baseline variables on the primary outcome will be analyzed: ACT, gender, age, quality of life (assessed via SGRQ Total Score), anxiety (assessed using GAD-7) and depression (assessed using PHQ-7). For all models, statistical model assumptions (linearity, homoscedasticity, normality of residuals) will be tested. If model assumptions are violated, appropriate analysis methods (e.g. robust regression, log-transformation) will be used.

Latent change models will be used for exploratory analyses of the course of the primary and the secondary outcomes in the follow-up longitudinal study [61, 62].

Economic evaluation

Data regarding resource utilization and work absenteeism will be documented retrospectively by the patient. A self-administrated questionnaire based on the FIMA questionnaire [52] has been developed specifically for patients with pulmonary problems. The monetary valuation of resource use will be based on the valuation rates calculated by Bock et al. [63]. Analysis of cost data will be performed with a model with a gamma distribution and a log-link to account for the skewed distribution of the data [64]. A 95% confidence interval for the cost difference will be estimated based on 1,000 bootstrap replications using the percentile method.

In the longitudinal follow-up study, the annual costs before and after rehabilitation will be compared by paired t-test. Alternatively, bootstrap resampling with 1,000 resamples will be used to compute p-values because cost differences may have a skewed distribution.

All statistical Analysis will be performed using SPSS [65], R [66] & SAS software [67].

Discussion

Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected

individuals [1]. Although effective medications are available, asthma remains incurable and poorly controlled for numerous patients in many countries [3, 4]. In Europe and in North America, asthma patients are commonly enrolled in PR programs [6] but the data available regarding PR of patients with asthma are sparse. This will be the first RCT to assess the effectiveness of a complex inpatient pulmonary rehabilitation regarding asthma control. The intervention conforms to the quality guidelines of the German Statutory Pension Insurance and follows national and international guidelines for pulmonary rehabilitation. Therefore, the results of this study may be generalizable. Furthermore, relevant medical and economic information will be generated for third-party payers, on which they can base their decisions regarding long-term management of asthma.

The findings of this study will be published in peer-reviewed journals and conference presentations.

Abbreviations

6-MWD: 6-Minute walk distance; AC: Asthma control; ACT: Asthma Control Test; AQLQ: Asthma Quality of Life Questionnaire; BFI: Brief Fatigue Inventory; B-IPQ: Brief-Illness Perception Questionnaire; BMQ: Brief Medication Questionnaire; CG: Control group; COPD: Chronic obstructive pulmonary disease; EQ-5D-5L: Euroqol Questionnaire; FeNO: Fractional exhaled nitric oxide; FEV₁: Forced expiration in one second; FEV₁/VC: FEV₁/FVC ratio, also called Tiffeneau-index; GAD: Generalized Anxiety Questionnaire; GRC: Global Rating of Change; heiQ: Health-Education Impact Questionnaire; IG: Intervention group; ImmunoCAP®: Measurement of specific IgE (Immunoglobulin E) antibody blood levels; HRQoL: Health related quality of life; MARS-D: Medication Adherence Report Scale; MID: Minimal important difference; PaCO₂: partial pressure of arterial carbon dioxide; PaO₂: partial pressure of arterial oxygen; PHQ: Patient Health Questionnaire; PR: Pulmonary Rehabilitation; QoL: Quality of Life; RCT: Randomized controlled trial; RV: Residual Volume; SGRQ: St. George Respiratory Questionnaire; SPE Scale: Subjective Prognostic Employment Scale; SPoRT: Subjektive prognosis of return to work; SRtot: Total specific resistance; Total Ig E: total Immunoglobulin E; VC: Vital capacity; WAI: Work Ability Index; WAS: Work Ability Score

Acknowledgements

We thank Dr. Renee Stark for the proofreading of the manuscript.

Funding

This work is supported by the German Statutory Pension Insurance of South Bavaria (Deutsche Rentenversicherung Bayern Süd), Am Alten Viehmarkt 2, D-84028 Landshut. Funding covers costs for staff and materials and traveling expenses.

Availability of data and materials

Not applicable.

Authors' contributions

KS initiated the study and obtained funding. He is principle investigator, supervises the study, the PR program and data collection. MS, HS, DN and MW contributed to the study concept and design. KS, MS and HS wrote the first draft of the manuscript, which was critically reviewed by DN and HF. MS participates in conducting the study and developing the design and statistical analysis plan. HS developed the study design regarding economic outcome parameters. DJ, RW and MW participate in conducting the study and in data collection. All authors participated in various steps in the study, edited the manuscript and gave their approval for submission.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The investigation conforms to the principles outlined in the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of the Bavarian Chamber of Physicians (Bayerische Landesärztekammer) on 21/04/2015 (Nr. 15017). After rehabilitation is approved, eligible patients will receive written information about all relevant aspects of the study and that their participation in the study is voluntary and they have the right to refuse or to withdraw their consent at any time without reprisals. Patients provide written informed consent. The study has been registered with the German Clinical Trials Register (DRKS00007740).

This paper contains the original study protocol. Any substantial modifications to the study protocol will be submitted to the Ethics Committee of the Bavarian Chamber of Physicians for approval prior to implementation. These amendments will be documented in detail in the German Clinical Trials Register and will be described transparently in trial reports.

Author details

¹Klinik Bad Reichenhall, Center for Rehabilitation, Pulmonology and Orthopedics, Bad Reichenhall, Germany. ²Institute of Health Economics and Health Care Management, Helmholtz Zentrum München (GmbH) - German Research Center for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany. ³Department of Medical Psychology and Psychotherapy, Medical Sociology and Rehabilitation Sciences Section, University of Würzburg, Würzburg, Germany. ⁴Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, LMU University of München, member DZL, German Centre for Lung Research, Munich, Germany.

Received: 24 January 2017 Accepted: 28 February 2017

Published online: 09 March 2017

References

1. (o.A.): Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2016. Available from: <http://www.ginasthma.org>. Accessed 5 Mar 2017.
2. British Thoracic S. Scottish Intercollegiate Guidelines N: British guideline on the management of asthma. *Thorax*. 2014;69 Suppl 1:1–192.
3. Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. *Eur Respir Rev*. 2012;21(123):66–74.
4. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and Link to Symptoms and Experience (REALISE) survey. *NPJ Prim Care Respir Med*. 2014;24:14009.
5. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, Holland AE, Lareau SC, Man WD, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med*. 2013;188(8):e13–64.
6. Spruit MA, Pitta F, Garvey C, ZuWallack RL, Roberts CM, Collins EG, Goldstein R, McNamara R, Surpas P, Atsuyoshi K, et al. Differences in content and organisational aspects of pulmonary rehabilitation programmes. *Eur Respir J*. 2014;43(5):1326–37.
7. Nathell L. Effects on sick leave of an inpatient rehabilitation programme for asthmatics in a randomized trial. *Scand J Public Health*. 2005;33(1):57–64.
8. Cambach W, Chadwick-Straver RV, Wagenaar RC, van Keimpema AR, Kemper HC. The effects of a community-based pulmonary rehabilitation programme on exercise tolerance and quality of life: a randomized controlled trial. *Eur Respir J*. 1997;10(1):104–13.
9. Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, Bauman A, Hensley MJ, Walters EH. Self-management education and regular practitioner review for adults with asthma. *Cochrane Database Syst Rev*. 2003;1:CD001117.
10. Powell H, Gibson PG. Options for self-management education for adults with asthma. *Cochrane Database Syst Rev*. 2003;1:CD004107.
11. Bott J, Blumenthal S, Buxton M, Ellum S, Falconer C, Garrod R, Harvey A, Hughes T, Lincoln M, Mikelsons C, et al. Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient. *Thorax*. 2009;64 Suppl 1:i1–51.

12. Bruurs ML, van der Giessen LJ, Moed H. The effectiveness of physiotherapy in patients with asthma: a systematic review of the literature. *Respir Med*. 2013;107(4):483–94.
13. Mendes FA, Goncalves RC, Nunes MP, Saraiva-Romanholo BM, Cukier A, Stelmach R, Jacob-Filho W, Martins MA, Carvalho CR. Effects of aerobic training on psychosocial morbidity and symptoms in patients with asthma: a randomized clinical trial. *Chest*. 2010;138(2):331–7.
14. Turner S, Eastwood P, Cook A, Jenkins S. Improvements in Symptoms and Quality of Life following Exercise Training in Older Adults with Moderate/ Severe Persistent Asthma. *Respiration*. 2011;81(4):302–10.
15. Avallone KM, McLeish AC. Asthma and aerobic exercise: a review of the empirical literature. *J Asthma*. 2013;50(2):109–16.
16. Carson KV, Chandratilleke MG, Picot J, Brinn MP, Esterman AJ, Smith BJ. Physical training for asthma. *Cochrane Database Syst Rev*. 2013;9:CD001116.
17. Franca-Pinto A, Mendes FA, de Carvalho-Pinto RM, Agondi RC, Cukier A, Stelmach R, Saraiva-Romanholo BM, Kaili J, Martins MA, Giavina-Bianchi P, et al. Aerobic training decreases bronchial hyperresponsiveness and systemic inflammation in patients with moderate or severe asthma: a randomised controlled trial. *Thorax*. 2015;70(8):732–9.
18. Eichenberger PA, Diener SN, Kofmehl R, Spengler CM. Effects of exercise training on airway hyperreactivity in asthma: a systematic review and meta-analysis. *Sports Med*. 2013;43(11):1157–70.
19. (o.A.): Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Asthma – Langfassung, 2. Auflage. Version 5. 2009, zuletzt geändert: August 2013. 2009. doi: 10.6101/AZQ/000163. Available from: <http://www.versorgungsleitlinien.de/themen/asthma>. cited:15 May 2016.
20. Emtner M, Finne M, Stalenheim G. A 3-year follow-up of asthmatic patients participating in a 10-week rehabilitation program with emphasis on physical training. *Arch Phys Med Rehabil*. 1998;79(5):539–44.
21. Emtner M, Herala M, Stalenheim G. High-intensity physical training in adults with asthma. A 10-week rehabilitation program. *Chest*. 1996;109(2):323–30.
22. Foglio K, Bianchi L, Bruletti G, Battista L, Pagani M, Ambrosino N. Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. *Eur Respir J*. 1999;13(1):125–32.
23. Renolleau-Courtois D, Lamouroux-Delay A, Delpierre S, Badier M, Lagier-Tessonier F, Palot A, Gouitaa M, Tummino C, Charpin D, Molinari N, et al. Home-based respiratory rehabilitation in adult patients with moderate or severe persistent asthma. *J Asthma*. 2014;51(5):552–8.
24. Trevor JL, Bhatt SP, Wells JM, Kirkpatrick D, Schumann C, Hitchcock J, Dransfield MT. Benefits of completing pulmonary rehabilitation in patients with asthma. *J Asthma*. 2015;52(9):969–73.
25. Lingner H, Ernst S, Grobetschennig A, Djahangiri N, Scheub D, Wittmann M, Schultz K. Asthma control and health-related quality of life one year after inpatient pulmonary rehabilitation: the ProKAR Study. *J Asthma*. 2015;52(6):614–21.
26. Ochmann U, Kotschy-Lang N, Raab W, Kellberger J, Nowak D, Jorres RA. Long-term efficacy of pulmonary rehabilitation in patients with occupational respiratory diseases. *Respiration*. 2012;84(5):396–405.
27. Farin E, Opitz U, Jäckel W, Gallenmüller K, Schwiensch M, Schultz K. Pneumological Rehabilitation: Long-term Data on Quality of Life and Predictors of Treatment Effects. *Phys Med Rehab Kuror*. 2009;19:75–84.
28. Schultz K. DGRW-update: relevance and evidence of pulmonary rehabilitation in chronic obstructive respiratory diseases (adults). *Rehabilitation (Stuttg)*. 2014;53(3):146–54.
29. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol*. 2004;113(1):59–65.
30. Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, Kosinski M, Pendergraft TB, Jhingran P. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. *J Allergy Clin Immunol*. 2006;117(3):549–56.
31. Bundesarbeitsgemeinschaft für Rehabilitation (BAR). Rahmenempfehlungen zur ambulanten pneumologischen Rehabilitation. 2008. http://www.barfrankfurt.de/fileadmin/dateiliste/publikationen/empfehlungen/downloads/Rahmenempfehlung_pneumologische_Reha.pdf. Accessed 5 Mar 2017.
32. Deutsche Rentenversicherung [German statutory pension insurance scheme]. Strukturqualität von Reha-Einrichtungen – Anforderungen der Deutschen Rentenversicherung [Quality of structure of rehabilitation centers - requirements of the German statutory pension insurance scheme]. 2. überarbeitete und erweiterte Auflage, Juli 2014. Available: http://www.deutsche-rentenversicherung.de/Allgemein/de/Inhalt/3_Infos_fuer_Experten/01_sozialmedizin_forschung/downloads/quali_strukturqualitaet/Broschuere_Strukturanforderungen.pdf?__blob=publicationFile&v=9. Accessed 5 Mar 2017.
33. Schatz M, Mosen DM, Kosinski M, Vollmer WM, Magid DJ, O'Connor E, Zeiger RS. Validity of the Asthma Control Test completed at home. *Am J Manag Care*. 2007;13(12):661–7.
34. Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. *J Allergy Clin Immunol*. 2009;124(4):719–23. e711.
35. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. *Am Rev Respir Dis*. 1992;145(6):1321–7.
36. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. *Chest*. 1999;115(5):1265–70.
37. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*. 2011;20(10):1727–36.
38. Oemar M, Janssen B. EQ-5D-5L User Guide 2013; (Version 2.0, October 2013). http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-5L_UserGuide_2015.pdf. Accessed 12 Dec 2016.
39. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. *J Man Manip Ther*. 2009;17(3):163–70.
40. Morris NR, Sabapathy S, Adams L, Kingsley RA, Schneider DA MSS. Verbal numerical scales are as reliable and sensitive as visual analog scales for rating dyspnea in young and older subjects. *Respir Physiol Neurobiol*. 2007;157(2-3):360–5.
41. Radbruch L, Sabatowski R, Elsner F, Everts J, Mendoza T, Cleeland C. Validation of the German version of the brief fatigue inventory. *J Pain Symptom Manage*. 2003;25(5):449–58.
42. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606–13.
43. Kroenke K, Spitzer RL, Williams JB, Lowe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. *Gen Hosp Psychiatry*. 2010;32(4):345–59.
44. Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. *Gen Hosp Psychiatry*. 2016;39:24–31.
45. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. *J Psychosom Res*. 2006;60(6):631–7.
46. Osborne RH, Elsworth GR, Whitfield K. The Health Education Impact Questionnaire (heiQ): an outcomes and evaluation measure for patient education and self-management interventions for people with chronic conditions. *Patient Educ Couns*. 2007;66(2):192–201.
47. Schuler M, Muekamp G, Faller H, Ehlebracht-König I, Gutenbrunner C, Kirchof R, Bengel J, Nolte S, Osborne RH, Schwarze M. Assessment of proximal outcomes of self-management programs: translation and psychometric evaluation of a German version of the Health Education Impact Questionnaire (heiQ). *Qual Life Res*. 2013;22(6):1391–403.
48. Mahler C, Hermann K, Horne R, Ludt S, Haefeli WE, Szecsenyi J, Jank S. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. *J Eval Clin Pract*. 2010;16(3):574–9.
49. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. *Patient Educ Couns*. 1999;37(2):113–24.
50. Crie CP, Baur X, Berdel D, Bosch D, Gappa M, Haidl P, Husemann K, Jorres RA, Kabitz HJ, Kardos P, et al. Standardization of spirometry: 2015 update. Published by German Atemwegsliga, German Respiratory Society and German Society of Occupational and Environmental Medicine. *Pneumologie*. 2015;69(3):147–64.
51. Crie CP, Soricther S, Smith HJ, Kardos P, Merget R, Heise D, Berdel D, Kohler D, Magnussen H, Marek W, et al. Body plethysmography—its principles and clinical use. *Respir Med*. 2011;105(7):959–71.
52. Seidl H, Bowles D, Bock JO, Bretschneider C, Greiner W, König HH, Holle R. FIMA-questionnaire for health-related resource use in an elderly population: development and pilot study. *Gesundheitswesen*. 2015;77(1):46–52.

53. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, McCormack MC, Carlin BW, Sciruba FC, Pitta F, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. *Eur Respir J*. 2014;44(6):1428–46.
54. Ilmarinen J. Work ability—a comprehensive concept for occupational health research and prevention. *Scand J Work Environ Health*. 2009;35(1):1–5.
55. Mittag O, Raspe H. A brief scale for measuring subjective prognosis of gainful employment: findings of a study of 4279 statutory pension insurees concerning reliability (Guttman scaling) and validity of the scale. *Rehabilitation (Stuttg)*. 2003;42(3):169–74.
56. Gupta SK. Intention-to-treat concept: A review. *Perspect Clin Res*. 2011;2(3):109–12.
57. van Buuren S. Flexible imputation of missing data. Boca Raton: CRC Press; 2012.
58. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c869.
59. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. Consolidated Standards of Reporting Trials G: CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol*. 2010;63(8):e1–37.
60. Frazier PA, Tix AP, Barron KE. Testing Moderator and Mediation Effects in Counseling Psychology Research. *J Couns Psychol*. 2004;51(1):115–34.
61. Bollen KA, Curran PJ. Latent curve models: a structural equation perspective. Hoboken, NJ: Wiley-Interscience; 2006.
62. Newsom JT. Longitudinal structural equation modeling. New York: Routledge; 2015.
63. Bock JO, Brettschneider C, Seidl H, Bowles D, Holle R, Greiner W, König HH. Calculation of standardised unit costs from a societal perspective for health economic evaluation. *Gesundheitswesen*. 2015;77(1):53–61.
64. Dodd S, Bassi A, Bodger K, Williamson P. A comparison of multivariable regression models to analyse cost data. *J Eval Clin Pract*. 2006;12(1):76–86.
65. IBM Corp. IBM SPSS Statistics for Windows, Version 23.0. Armonk: IBM Corp.; 2014.
66. R Development Core Team: R. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016.
67. SAS Institute, Inc., Cary, NC, <http://www.sas.com>.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

